Clinical trials: sponsored by Zhejiang Cancer Hospital
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Tumor
Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
The tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database.
- Trial name
- NCT04793672
- Testing
- Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
- Where
- 2 sites in China
- Volunteers
- 4,100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer (OvCa)
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in…
- Trial name
- RESO (NCT07586449)
- Testing
- Senaparib capsules(20mg)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
High-risk R/R LBCL
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk…
- Trial name
- CAR-T+ASCT (NCT07538635)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
MALT Lymphoma
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
This is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma.
- Trial name
- NCT07554898
- Testing
- Orelabrutinib, Ultra-low-dose Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Neoplasms
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers
This study aims to develop a pan-cancer screening model using routine blood biomarkers (including complete blood count, biochemical tests, coagulation panel, and tumor markers).
- Trial name
- PanCanBlood (NCT07554157)
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Cancer
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
Evaluate the initial dose-effect and time-effect relationship of the injection product NC527-X
- Trial name
- NCT07538648
- Testing
- Experimental:Preoperative injection of NC527-X
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Cancer Hospital
Hypotension on Induction, Old Age
Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
This study investigated the effect of Trendelenburg position on preventing post-induction hypotension in elderly patients undergoing abdominal surgery with general anesthesia.
- Trial name
- NCT06968091
- Testing
- Trendelenburg position, Supine Horizontal Position
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Zhejiang Cancer Hospital
Diffuse Large B-Cell Lymphoma (DLBCL), Intrathecal Chemotherapy
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
This is a prospective, single-arm clinical study to evaluate the efficacy and safety of intrathecal thiotepa for the prevention of central nervous system (CNS) involvement in patients with high-aggressive B-cell lymphoma.
- Trial name
- NCT07493486
- Testing
- (RCHOP or an investigator's choice) plus IT thiotepa and dexamethasone
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
This study adopts a multicenter, natural selection, observational design, and plans to enroll patients with HER-2 positive advanced or metastatic breast cancer treated at approximately 20 research centers nationwide.
- Trial name
- NCT07455188
- Testing
- Antitumor treatment plan
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer, Cytoreductive Surgery
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer.
- Conditions
- Ovarian Cancer, Cytoreductive Surgery, Depressive Symptom
- Trial name
- NCT06624878
- Testing
- esketamine
- Where
- China
- Volunteers
- 568 people
- Sponsor
- Zhejiang Cancer Hospital
Pirtobrutinib, Sintilimab
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
This is a prospective, single-Arm, phase II clinical study evaluating the efficacy and safety of thiotepa in combination with pirtobrutinib (a BTK Inhibitor) and sintilimab (a PD-1 Inhibitor) for frail or relapsed/refractory…
- Conditions
- Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
- Trial name
- NCT07416890
- Testing
- Thiotepa, Pirtobrutinib , Sintilimab(TPS)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Metastatic
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.
- Trial name
- SACIT-OUT (NCT06784921)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
- Trial name
- NCT07343479
- Testing
- sac-TMT plus EGFR-TKI
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
This study was an open, multicenter phase II clinical trial that enrolled 118 patients with HR+/HER2- with recurrent or progressive advanced breast cancer treated with CDK4/6 inhibitors; The study adopted the Simon phase 2…
- Trial name
- NCT07330544
- Testing
- entinostat, Fulvestrant, Anlotinib
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreatic Cancer Resectable, Pancreatic Cancer Non-resectable
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
This study is a single-center, observational clinical trial designed to enroll a total of 70 pancreatic cancer patients. Tumor tissue sections from 60 patients will be retrospectively collected to establish a treatment response…
- Trial name
- NCT07326150
- Testing
- Sample Collection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang Cancer Hospital
Anesthesia, Airway Remodeling
GMA-Tulip, I-gel and the LMA-Supreme (LMA-S) Devices in Airway Management (GLAM-I)
Patients were randomly assigned to three supraglottic airway devices (SADs) groups for airway management after anesthesia induced.
- Trial name
- GLAM-I (NCT06383494)
- Testing
- LMA supreme group, I-gel group, GMA-Tulip
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Zhejiang Cancer Hospital
IBI363 + Chemotherapy
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative…
- Trial name
- NCT07325630
- Testing
- IBI363 + chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatic Artery Infusion, Liver Metastasis of Breast Cancer
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
Study Objective: To Evaluate the Efficacy of Albumin-Bound Paclitaxel Combined with Nedaplatin via Hepatic Arterial Infusion as Later-Line Therapy for Breast Cancer Patients with Liver Metastases After Failure of Standard…
- Trial name
- NCT07284836
- Testing
- Abraxane, Nedaplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer, HER2
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Ovarian cancer exhibits the highest mortality rate among gynecological malignancies. Currently, the combination of paclitaxel and carboplatin remains the standard first-line chemotherapy regimen for neoadjuvant or postoperative…
- Trial name
- NCT07285941
- Testing
- RC48 + Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital